ZEJULA (niraparib) capsules

ZEJULA capsules/tablets are a prescription medicine used for the: maintenance treatment of adults with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. ZEJULA is used after the cancer has responded (complete or partial response) to treatment with platinum-based chemotherapy. FDA approved niraparib (brand name ZEJULA) is not (yet) registered or available in India but on request Indian patient can buy ZEJULA at the lowest price.

Home | niraparib capsules

ZEJULA (niraparib) capsules Price In India Ahmedabad Bengaluru Chennai Kolkata Mumbai
ZEJULA (niraparib) capsules

Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!

For Indian Patient Enquiry under NPP.

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

ZEJULA (niraparib) capsules

Niraparib is a chemotherapy medication that stops cancer cells from growing. It treats ovarian cancer, fallopian tube cancer and peritoneal cancer.

ZEJULA is a prescription medicine used for the:
• maintenance treatment of adults with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
• maintenance treatment of adults with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that comes back.
• treatment of adults with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.

  • Niraparib is indicated for the maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
  • In October 2019, the indication for niraparib was expanded to include people with advanced ovarian, fallopian tube, or primary peritoneal cancer treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD)-positive status.
  • In April 2020, the indication for niraparib was expanded to include the maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.
  • In the European Union, niraparib is indicated: as monotherapy for the maintenance treatment of adults with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer.

Drug (Brand / Generic): ZEJULA / niraparib
Current Indication: treat ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
Approval Date: Aug 1, 2017

GlaxoSmithKline
Capsules: 100 mg

ZEJULA is available as capsules having a white body printed with “100 mg” in black ink, and a purple cap printed with “Niraparib” in white ink.
Each capsule contains 100 mg of niraparib free base.
ZEJULA capsules are packaged as
• 90-count bottles NDC 69656-103-90
• 30-count bottles NDC 69656-103-30
Store at 20°C to 25°C (68°F to 77°F);

For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here

Alleviare Life Sciences

About Us

Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.

Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.

Alleviare India, a certified pharmaceutical facilitator / supplier / importer of specialty medicines or drugs based in India.